Pharmaceutical compositions for the treatment of asthma

A metered dose inhaler containing an aerosol suspension formulation for inhalation, said aerosol suspension formulation for inhalation comprising:

• an effective amount of mometasone furoate;
• an effective amount of formoterol fumarate;
• a bulking agent present in an amount of about 0.05% to 0.3% by weight of the formulation;
• and 1,1,1,2-tetrafluoroethane;
• wherein the ratio of mometasone furoate to formoterol fumarate is about 400 μg of mometasone furoate to about 12 μg of formoterol fumarate to about 50 μg of mometasone furoate to about 6 μg of formoterol fumarate, and wherein the formoterol fumarate flocculates with the mometasone furoate.

A process for producing an aerosol suspension formulation for inhalation, said aerosol suspension formulation for inhalation comprising:

• an effective amount of mometasone furoate;
• an effective amount of formoterol fumarate;
• and 1,1,1,2,3,3,3,-heptaflouopropane;
• wherein the ratio of mometasone furoate to formoterol fumarate is about 400 μg of mometasone furoate to about 12 μg of formoterol fumarate to about 50 μg of mometasone furoate to about 6 μg of formoterol fumarate, wherein the formoterol fumarate is flocculated with the mometasone furoate in said aerosol suspension formulation, and wherein the formulation is free of a bulking agent, comprising the steps of:
• a) mixing a dry powder blend of micronized mometasone furoate and formoterol fumarate with a dry powder surfactant to form a uniform mixture;
• b) filling said mixture into a metered dose inhaler canister;
• c) crimping said canister with a metering valve;
• and
• d) filling said canister with a nonchlorofluorocarbon propellant.

A metered dose inhaler containing an aerosol suspension formulation for inhalation, said aerosol suspension formulation for inhalation comprising:

• an effective amount of mometasone furoate;
• an effective amount of formoterol fumarate;
• a dry powder surfactant;
• and 1,1,1,2,3,3,3,-heptaflouopropane;
• wherein the ratio of mometasone furoate to formoterol fumarate is about 400 μg of mometasone furoate to about 12 μg of formoterol fumarate to about 50 μg of mometasone furoate to about 6 μg of formoterol fumarate, wherein the formoterol fumarate flocculates with the mometasone furoate, wherein the formulation is free of additional excipients, and wherein the metered dose inhaler emits a dose having uniform drug content upon actuation of the metered dose inhaler.

A metered dose inhaler containing an aerosol suspension formulation for inhalation, said aerosol suspension formulation for inhalation comprising:

• an effective amount of mometasone furoate;
• an effective amount of formoterol fumarate;
• and 1,1,1,2,3,3,3,-heptaflouopropane;
• wherein the ratio of mometasone furoate to formoterol fumarate is about 400 μg of mometasone furoate to about 12 μg of formoterol fumarate to about 50 μg of mometasone furoate to about 6 μg of formoterol fumarate, wherein the formoterol fumarate flocculates with the mometasone furoate, and wherein the formulation contains less than 0.1% of an epoxide degradation product of mometasone furoate.

A metered dose inhaler containing an aerosol suspension formulation for inhalation, said aerosol suspension formulation for inhalation comprising:

• an effective amount of mometasone furoate;
• an effective amount of formoterol fumarate;
• and 1,1,1,2,3,3,3,-heptaflouopropane;
• wherein the ratio of mometasone furoate to formoterol fumarate is about 400 μg of mometasone furoate to about 12 μg of formoterol fumarate to about 50 μg of mometasone furoate to about 6 μg of formoterol fumarate, wherein the formoterol fumarate flocculates with the mometasone furoate, wherein the percent of the fine particles dispensed upon actuation of the metered dose inhaler is about 55% to about 85%, and wherein said fine particles have a particle size of less than about 4.7 μm.